低侵襲生検技術の世界市場の評価：提供製品別、技術別、循環バイオマーカー別、用途別、エンドユーザー別、地域別、機会、予測（2016年～2030年）

世界の低侵襲生検技術の市場規模は、2022年の38億9,000万米ドルから2030年に69億3,000万米ドルに達し、2023年～2030年の予測期間にCAGRで7.49%の成長が予測されています。市場の大幅な成長は、世界中でのがんの流行などの要因によって促進されています。

当レポートでは、世界の低侵襲生検技術市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢と見通しなどを提供しています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 COVID-19の影響

第4章 ロシア・ウクライナ戦争の影響

第5章 エグゼクティブサマリー

第6章 世界の低侵襲生検技術市場の見通し（2016年～2030年）

• 市場規模と予測
  • 金額
• 提供製品別
  • 検査
  • キット・消耗品
  • 器具
• 技術別
  • リキッドバイオプシー
  • 光生検
  • ブラシ生検
  • 色素性病変アッセイ
  • その他
• 循環バイオマーカー別
  • 循環腫瘍細胞（CTC）
  • 無細胞DNA（cfDNA）
  • 循環腫瘍DNA（ctDNA）
  • 細胞外小胞
  • その他
• 用途別
  • 臨床
  • 治療
• エンドユーザー別
  • 病院・診療所
  • 学術・研究機関
  • 外来診療センター
• 地域別
  • 北米
  • 欧州
  • 南米
  • アジア太平洋
  • 中東・アフリカ
• 市場シェア：企業別（2022年）

第7章 世界の低侵襲生検技術市場の見通し：地域別（2016年～2030年）

• 北米
  • 提供製品別
  • 技術別
  • 循環バイオマーカー別
  • 用途別
  • エンドユーザー別
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • フランス
  • イタリア
  • 英国
  • ロシア
  • オランダ
  • スペイン
  • トルコ
  • ポーランド
• 南米
  • ブラジル
  • アルゼンチン
• アジア太平洋
  • インド
  • 中国
  • 日本
  • オーストラリア
  • ベトナム
  • 韓国
  • インドネシア
  • フィリピン
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • 南アフリカ

第8章 市場マッピング（2022年）

• 提供製品別
• 技術別
• 循環バイオマーカー別
• 用途別
• エンドユーザー別
• 地域別

第9章 マクロ環境と業界構造

• 需給の分析
• 輸出入の分析
• サプライ/バリューチェーン分析
• PESTEL分析
• ポーターのファイブフォース分析

第10章 市場力学

• 成長促進要因
• 成長抑制要因（課題、抑制要因）

第11章 主要企業情勢

• マーケットリーダー上位5社の競合マトリックス
• マーケットリーダー上位5社の市場の収益分析（2022年）
• 合併と買収/合弁事業（該当する場合）
• SWOT分析（市場参入企業5社向け）
• 特許分析（該当する場合）

第12章 価格分析

第13章 ケーススタディ

第14章 主要企業の見通し

• Thermo Fisher Scientific, Inc.
• F. Hoffmann-La Roche AG
• QIAGEN NV
• Guardant Health, Inc.
• Veracyte, Inc.
• Myriad Genetics, Inc.
• Biocept, Inc.
• NeoGenomics Laboratories, Inc.
• Adaptive Biotechnologies Corporation
• DermTech, Inc.

第15章 戦略的推奨事項

第16章 当社について・免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F
• Figure 2. Global Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F
• Figure 3. Global Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F
• Figure 4. Global Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F
• Figure 5. Global Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F
• Figure 6. Global Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F
• Figure 7. Global Minimally Invasive Biopsy Techniques Market Share, By Region, In USD Billion, 2016-2030F
• Figure 8. North America Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F
• Figure 9. North America Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F
• Figure 10. North America Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F
• Figure 11. North America Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F
• Figure 12. North America Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F
• Figure 13. North America Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F
• Figure 14. North America Minimally Invasive Biopsy Techniques Market Share, By Country, In USD Billion, 2016-2030F
• Figure 15. United States Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F
• Figure 16. United States Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F
• Figure 17. United States Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F
• Figure 18. United States Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F
• Figure 19. United States Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F
• Figure 20. United States Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F
• Figure 21. Canada Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F
• Figure 22. Canada Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F
• Figure 23. Canada Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F
• Figure 24. Canada Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F
• Figure 25. Canada Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F
• Figure 26. Canada Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F
• Figure 27. Mexico Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F
• Figure 28. Mexico Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F
• Figure 29. Mexico Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F
• Figure 30. Mexico Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F
• Figure 31. Mexico Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F
• Figure 32. Mexico Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F
• Figure 33. Europe Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F
• Figure 34. Europe Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F
• Figure 35. Europe Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F
• Figure 36. Europe Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F
• Figure 37. Europe Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F
• Figure 38. Europe Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F
• Figure 39. Europe Minimally Invasive Biopsy Techniques Market Share, By Country, In USD Billion, 2016-2030F
• Figure 40. Germany Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F
• Figure 41. Germany Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F
• Figure 42. Germany Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F
• Figure 43. Germany Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F
• Figure 44. Germany Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F
• Figure 45. Germany Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F
• Figure 46. France Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F
• Figure 47. France Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F
• Figure 48. France Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F
• Figure 49. France Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F
• Figure 50. France Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F
• Figure 51. France Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F
• Figure 52. Italy Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F
• Figure 53. Italy Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F
• Figure 54. Italy Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F
• Figure 55. Italy Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F
• Figure 56. Italy Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F
• Figure 57. Italy Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F
• Figure 58. United Kingdom Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F
• Figure 59. United Kingdom Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F
• Figure 60. United Kingdom Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F
• Figure 61. United Kingdom Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F
• Figure 62. United Kingdom Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F
• Figure 63. United Kingdom Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F
• Figure 64. Russia Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F
• Figure 65. Russia Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F
• Figure 66. Russia Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F
• Figure 67. Russia Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F
• Figure 68. Russia Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F
• Figure 69. Russia Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F
• Figure 70. Netherlands Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F
• Figure 71. Netherlands Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F
• Figure 72. Netherlands Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F
• Figure 73. Netherlands Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F
• Figure 74. Netherlands Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F
• Figure 75. Netherlands Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F
• Figure 76. Spain Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F
• Figure 77. Spain Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F
• Figure 78. Spain Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F
• Figure 79. Spain Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F
• Figure 80. Spain Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F
• Figure 81. Spain Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F
• Figure 82. Turkey Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F
• Figure 83. Turkey Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F
• Figure 84. Turkey Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F
• Figure 85. Turkey Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F
• Figure 86. Turkey Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F
• Figure 87. Turkey Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F
• Figure 88. Poland Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F
• Figure 89. Poland Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F
• Figure 90. Poland Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F
• Figure 91. Poland Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F
• Figure 92. Poland Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F
• Figure 93. Poland Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F
• Figure 94. South America Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F
• Figure 95. South America Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F
• Figure 96. South America Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F
• Figure 97. South America Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F
• Figure 98. South America Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F
• Figure 99. South America Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F
• Figure 100. South America Minimally Invasive Biopsy Techniques Market Share, By Country, In USD Billion, 2016-2030F
• Figure 101. Brazil Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F
• Figure 102. Brazil Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F
• Figure 103. Brazil Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F
• Figure 104. Brazil Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F
• Figure 105. Brazil Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F
• Figure 106. Brazil Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F
• Figure 107. Argentina Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F
• Figure 108. Argentina Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F
• Figure 109. Argentina Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F
• Figure 110. Argentina Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F
• Figure 111. Argentina Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F
• Figure 112. Argentina Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F
• Figure 113. Asia-Pacific Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F
• Figure 114. Asia-Pacific Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F
• Figure 115. Asia-Pacific Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F
• Figure 116. Asia-Pacific Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F
• Figure 117. Asia-Pacific Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F
• Figure 118. Asia- Pacific Cream Market Share, By End-user, In USD Billion, 2016-2030F
• Figure 119. Asia-Pacific Minimally Invasive Biopsy Techniques Market Share, By Country, In USD Billion, 2016-2030F
• Figure 120. India Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F
• Figure 121. India Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F
• Figure 122. India Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F
• Figure 123. India Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F
• Figure 124. India Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F
• Figure 125. India Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F
• Figure 126. China Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F
• Figure 127. China Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F
• Figure 128. China Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F
• Figure 129. China Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F
• Figure 130. China Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F
• Figure 131. China Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F
• Figure 132. Japan Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F
• Figure 133. Japan Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F
• Figure 134. Japan Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F
• Figure 135. Japan Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F
• Figure 136. Japan Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F
• Figure 137. Japan Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F
• Figure 138. Australia Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F
• Figure 139. Australia Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F
• Figure 140. Australia Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F
• Figure 141. Australia Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F
• Figure 142. Australia Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F
• Figure 143. Australia Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F
• Figure 144. Vietnam Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F
• Figure 145. Vietnam Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F
• Figure 146. Vietnam Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F
• Figure 147. Vietnam Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F
• Figure 148. Vietnam Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F
• Figure 149. Vietnam Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F
• Figure 150. South Korea Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F
• Figure 151. South Korea Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F
• Figure 152. South Korea Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F
• Figure 153. South Korea Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F
• Figure 154. South Korea Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F
• Figure 155. South Korea Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F
• Figure 156. Indonesia Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F
• Figure 157. Indonesia Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F
• Figure 158. Indonesia Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F
• Figure 159. Indonesia Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F
• Figure 160. Indonesia Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F
• Figure 161. Indonesia Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F
• Figure 162. Philippines Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F
• Figure 163. Philippines Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F
• Figure 164. Philippines Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F
• Figure 165. Philippines Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F
• Figure 166. Philippines Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F
• Figure 167. Philippines Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F
• Figure 168. Middle East & Africa Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F
• Figure 169. Middle East & Africa Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F
• Figure 170. Middle East & Africa Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F
• Figure 171. Middle East & Africa Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F
• Figure 172. Middle East & Africa Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F
• Figure 173. Middle East & Africa Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F
• Figure 174. Middle East & Africa Minimally Invasive Biopsy Techniques Market Share, By Country, In USD Billion, 2016-2030F
• Figure 175. Saudi Arabia Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F
• Figure 176. Saudi Arabia Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F
• Figure 177. Saudi Arabia Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F
• Figure 178. Saudi Arabia Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F
• Figure 179. Saudi Arabia Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F
• Figure 180. Saudi Arabia Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F
• Figure 181. UAE Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F
• Figure 182. UAE Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F
• Figure 183. UAE Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F
• Figure 184. UAE Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F
• Figure 185. UAE Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F
• Figure 186. UAE Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F
• Figure 187. South Africa Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F
• Figure 188. South Africa Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F
• Figure 189. South Africa Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F
• Figure 190. South Africa Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F
• Figure 191. South Africa Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F
• Figure 192. South Africa Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F
• Figure 193. By Product Offered Map-Market Size (USD Billion) & Growth Rate (%), 2022
• Figure 194. By Technique Map-Market Size (USD Billion) & Growth Rate (%), 2022
• Figure 195. By Circulating Biomarker Map-Market Size (USD Billion) & Growth Rate (%), 2022
• Figure 196. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2022
• Figure 197. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2022
• Figure 198. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2022

Global Minimally Invasive Biopsy Techniques Market size was valued at USD 3.89 billion in 2022 which is expected to reach USD 6.93 billion in 2030 with a CAGR of 7.49% for the forecast period between 2023 and 2030. Significant growth in the market is driven by several factors such as the increasing prevalence of cancer worldwide and is marked by notable advancements. The development of imaging-guided biopsy techniques, such as ultrasound-guided and MRI-guided biopsies, has enhanced the precision and accuracy of tissue sampling. These techniques allow for real-time visualization of the biopsy site, enabling physicians to target specific lesions and obtain high-quality samples. Additionally, the integration of robotics and artificial intelligence (AI) has further refined the biopsy process, enhanced procedural efficiency, and reduced human error. Furthermore, there have been notable developments in the field of liquid biopsy, which involves the analysis of circulating tumor cells, cell-free DNA, or other biomarkers in the blood.

For example, Roche launched the FoundationOne®Liquid CDx test, a comprehensive liquid biopsy assay. It employs next-generation sequencing to detect multiple genetic alterations in ctDNA extracted from blood samples. The test is designed to identify genomic alterations in solid tumors, aiding in the selection of targeted therapies and monitoring treatment response.

Minimally invasive biopsy techniques refer to procedures that enable the extraction of tissue samples for diagnostic purposes with minimal damage to surrounding tissues and reduced patient discomfort. Minimally invasive biopsy techniques offer a less invasive alternative to traditional open suragical biopsies, making them more appealing to patients and physicians.

Increase Demand for Early and Accurate Diagnosis:

Early and accurate diagnosis is crucial for successful treatment outcomes in various medical conditions, including cancer. Minimally invasive biopsy techniques offer a less invasive and safer alternative to traditional biopsy techniques, making it a preferred choice for patients and healthcare providers. By detecting the presence of cancer cells at an early stage, the minimally invasive biopsy technique can help initiate timely and appropriate treatment, which can significantly improve patient outcomes. Therefore, increasing awareness among patients and healthcare providers about the benefits of early and accurate diagnosis through minimally invasive biopsy techniques can lead to a rise in demand for these techniques in the Global Minimally Invasive Biopsy Technique Market. Additionally, research and development to improve the accuracy and effectiveness of these techniques can further drive demand and market growth.

Technological Advancements:

The Global Minimally Invasive Biopsy Techniques Market has seen significant technological advancements in recent years. One of the most notable developments has been the introduction of robotic-assisted biopsy systems that enable more accurate and less invasive procedures. Additionally, the development of advanced imaging technologies, such as ultrasound and magnetic resonance imaging (MRI), has improved the accuracy of biopsies and reduced the need for more invasive procedures. Other technological advancements, such as the use of disposable biopsy needles and the development of real-time image guidance systems, have also improved the safety and efficiency of minimally invasive biopsies. These technological advancements are expected to continue to drive growth in the market in the coming years.

Liquid Biopsy Segment Leads the Market:

Tissue biopsies are the gold standard for diagnosing cancer and profiling tumours. Despite this, biopsy procedures have been linked to a number of limitations, prompting a demand for less intrusive and more precise alternatives. Liquid biopsies are a promising contender for determining the prognosis and diagnosis of cancer in patients. Because of the large number of analytes flowing in the bloodstream that may be employed for liquid biopsy testing, it is a promising tool for the clinical care of oncological patients. Several companies focus on the launch of new liquid biopsy products in line with the same. 

For example, BillionToOne, a molecular diagnostics company, launched a range of Oncology liquid biopsy products Northstar Response and Northstar Select in July 2022. Northstar Response offers a tissue-independent therapy response monitoring test, whereas Northstar Select is a thorough pan-cancer somatic mutation screening panel. Both items are now accessible for usage in research at a few prestigious academic cancer centres.

Cell Free DNA (cfDNA) Segment Dominates:

The cell-free DNA segment is set to dominate the global market for minimally invasive biopsy procedures. cfDNA is the fragmented DNA delivered into the circulation by cells dying naturally or as a result of illnesses such as cancer. Several reasons contribute to this segment's dominance. For a start, cfDNA analysis provides an alternative to standard tissue biopsies, removing the necessity for invasive surgeries and decreasing patient suffering. Secondly, cfDNA analysis allows for real-time monitoring of disease progression, treatment response, and detection of genetic abnormalities, making it a valuable tool for personalized medicine. Furthermore, advancements in technology, such as next-generation sequencing (NGS) and digital PCR, have improved the sensitivity and accuracy of cfDNA analysis, further driving its adoption and market dominance. The widespread applicability and benefits of cfDNA analysis position it as a leading segment in the global minimally invasive biopsy techniques market.

Government Initiatives:

In order to increase political commitment to cancer prevention and control on a worldwide scale, WHO and IARC have worked together with other UN organizations. In addition to working with other UN organisations, such as the International Atomic Energy Agency, to track cancer prevalence (as part of the Global Initiative on Cancer Registries' activities), it aims to reach out to nations where data is scarce by conducting research on the causes of human cancer and the mechanisms of carcinogenesis.

Additionally, it focuses on identifying the "best buys" and other high-priority, cost-effective cancer prevention and control measures, such as minimally invasive biopsy techniques, and it also offers guidelines and standards to guide the creation and implementation of programmes for cancer prevention, early detection, screening, treatment, palliative care, and survivorship care in both adults and children. The effort also include raising awareness about the use of minimally invasive biopsy methods to improve access to cancer therapies by supporting regional and governmental health systems.

Impact of COVID-19:

The market for minimally invasive biopsy techniques has been significantly impacted by the COVID-19 Pandemic which disrupted the global supply chain of medical devices and equipment, resulting in a decrease in the availability of minimally invasive biopsy devices. The delay or cancellation of elective procedures has led to a decrease in demand for minimally invasive biopsy procedures. Additionally, the shift towards telemedicine and virtual consultations has also impacted the market. However, the pandemic has also increased the demand for diagnostic testing, including minimally invasive biopsies, to diagnose and monitor COVID-19-related complications.

Impact of Russia-Ukraine War:

The Russia-Ukraine war had a limited impact on the global minimally invasive biopsy techniques market. While Ukraine is a significant manufacturer of medical devices, including minimally invasive biopsy devices, the global market has not been heavily affected. The war has disrupted the supply chain of medical devices and equipment in Ukraine, leading to a decrease in the availability of these devices in the region. However, the impact on the global market has been minimal as other countries continue to manufacture and supply these devices. It is worth noting that the ongoing conflict has also led to a decrease in demand for medical procedures in Ukraine, including minimally invasive biopsies, due to the strain on the healthcare system and limited access to medical facilities in conflict-affected areas.

Key Player Landscape and Outlook:

Multiple prominent manufacturers are fighting for market share in the highly competitive market for minimally invasive biopsy procedures. The companies offer a wide range of minimally invasive biopsy devices and compete based on product quality, innovation, and pricing. In recent years, there has been a significant focus on product development and innovation, with companies investing in research and development to develop new and advanced minimally invasive biopsy devices. The market is also characterized by strategic collaborations, partnerships, and mergers and acquisitions, with companies seeking to expand their product portfolios and geographic reach.

For instance, Biocept is a prominent commercial supplier of testing services that allow doctors to discover and track cancer biomarkers in cerebrospinal fluid samples. Biocept's test menu, via CNSideTM, emphasises cancer biomarkers that are clinically actionable according to clinical treatment criteria established by the NCCN® (National Comprehensive Cancer Network®).

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Impact of COVID-19

4. Impact of Russia-Ukraine War

5. Executive Summary

6. Global Minimally Invasive Biopsy Techniques Market Outlook, 2016-2030F

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. By Product Offered
  • 6.2.1. Tests
  • 6.2.2. Kits & Consumables
  • 6.2.3. Instruments
• 6.3. By Technique
  • 6.3.1. Liquid Biopsy
  • 6.3.2. Optical Biopsy
  • 6.3.3. Brush Biopsy
  • 6.3.4. Pigmented Lesion Assays
  • 6.3.5. Others
• 6.4. By Circulating Biomarker
  • 6.4.1. Circulating Tumor Cells (CTCs)
  • 6.4.2. Cell Free DNA (cfDNA)
  • 6.4.3. Circulating Tumor DNA (ctDNA)
  • 6.4.4. Extracellular Vesicles
  • 6.4.5. Others
• 6.5. By Application
  • 6.5.1. Clinical
    • 6.5.1.1. Treatment Monitoring
    • 6.5.1.2. Prognosis & Recurrence Monitoring
    • 6.5.1.3. Treatment Selection
    • 6.5.1.4. Others
  • 6.5.2. Therapeutic
    • 6.5.2.1. Lung Cancer
    • 6.5.2.2. Breast Cancer
    • 6.5.2.3. Prostate Cancer
    • 6.5.2.4. Colorectal Cancer
    • 6.5.2.5. Others
• 6.6. By End-user
  • 6.6.1. Hospitals & Clinics
  • 6.6.2. Academic & Research Institutions
  • 6.6.3. Ambulatory Care Centers
• 6.7. By Region
  • 6.7.1. North America
  • 6.7.2. Europe
  • 6.7.3. South America
  • 6.7.4. Asia-Pacific
  • 6.7.5. Middle East & Africa
• 6.8. By Company Market Share (%), 2022

7. Global Minimally Invasive Biopsy Techniques Market Outlook, By Region, 2016-2030F

• 7.1. North America*
  • 7.1.1. By Product Offered
    • 7.1.1.1. Tests
    • 7.1.1.2. Kits & Consumables
    • 7.1.1.3. Instruments
  • 7.1.2. By Technique
    • 7.1.2.1. Liquid Biopsy
    • 7.1.2.2. Optical Biopsy
    • 7.1.2.3. Brush Biopsy
    • 7.1.2.4. Pigmented Lesion Assays
    • 7.1.2.5. Others
  • 7.1.3. By Circulating Biomarker
    • 7.1.3.1. Circulating Tumor Cells (CTCs)
    • 7.1.3.2. Cell Free DNA (cfDNA)
    • 7.1.3.3. Circulating Tumor DNA (ctDNA)
    • 7.1.3.4. Extracellular Vesicles
    • 7.1.3.5. Others
  • 7.1.4. By Application
    • 7.1.4.1. Clinical
    • 7.1.4.1.1. Treatment Monitoring
    • 7.1.4.1.2. Prognosis & Recurrence Monitoring
    • 7.1.4.1.3. Treatment Selection
    • 7.1.4.1.4. Others
    • 7.1.4.2. Therapeutic
    • 7.1.4.2.1. Lung Cancer
    • 7.1.4.2.2. Breast Cancer
    • 7.1.4.2.3. Prostate Cancer
    • 7.1.4.2.4. Colorectal Cancer
    • 7.1.4.2.5. Others
  • 7.1.5. By End-user
    • 7.1.5.1. Hospitals & Clinics
    • 7.1.5.2. Academic & Research Institutions
    • 7.1.5.3. Ambulatory Care Centers
  • 7.1.6. United States*
    • 7.1.6.1. By Product Offered
    • 7.1.6.1.1. Tests
    • 7.1.6.1.2. Kits & Consumables
    • 7.1.6.1.3. Instruments
    • 7.1.6.2. By Technique
    • 7.1.6.2.1. Liquid Biopsy
    • 7.1.6.2.2. Optical Biopsy
    • 7.1.6.2.3. Brush Biopsy
    • 7.1.6.2.4. Pigmented Lesion Assays
    • 7.1.6.2.5. Others
    • 7.1.6.3. By Circulating Biomarker
    • 7.1.6.3.1. Circulating Tumor Cells (CTCs)
    • 7.1.6.3.2. Cell Free DNA (cfDNA)
    • 7.1.6.3.3. Circulating Tumor DNA (ctDNA)
    • 7.1.6.3.4. Extracellular Vesicles
    • 7.1.6.3.5. Others
    • 7.1.6.4. By Application
    • 7.1.6.4.1. Clinical
    • 7.1.6.4.1.1. Treatment Monitoring
    • 7.1.6.4.1.2. Prognosis & Recurrence Monitoring
    • 7.1.6.4.1.3. Treatment Selection
    • 7.1.6.4.1.4. Others
    • 7.1.6.4.2. Therapeutic
    • 7.1.6.4.2.1. Lung Cancer
    • 7.1.6.4.2.2. Breast Cancer
    • 7.1.6.4.2.3. Prostate Cancer
    • 7.1.6.4.2.4. Colorectal Cancer
    • 7.1.6.4.2.5. Others
    • 7.1.6.5. By End-user
    • 7.1.6.5.1. Hospitals & Clinics
    • 7.1.6.5.2. Academic & Research Institutions
    • 7.1.6.5.3. Ambulatory Care Centers
  • 7.1.7. Canada
  • 7.1.8. Mexico

All segments will be provided for all regions and countries covered

• 7.2. Europe
  • 7.2.1. Germany
  • 7.2.2. France
  • 7.2.3. Italy
  • 7.2.4. United Kingdom
  • 7.2.5. Russia
  • 7.2.6. Netherlands
  • 7.2.7. Spain
  • 7.2.8. Turkey
  • 7.2.9. Poland
• 7.3. South America
  • 7.3.1. Brazil
  • 7.3.2. Argentina
• 7.4. Asia-Pacific
  • 7.4.1. India
  • 7.4.2. China
  • 7.4.3. Japan
  • 7.4.4. Australia
  • 7.4.5. Vietnam
  • 7.4.6. South Korea
  • 7.4.7. Indonesia
  • 7.4.8. Philippines
• 7.5. Middle East & Africa
  • 7.5.1. Saudi Arabia
  • 7.5.2. UAE
  • 7.5.3. South Africa

8. Market Mapping, 2022

• 8.1. By Product Offered
• 8.2. By Technique
• 8.3. By Circulating Biomarker
• 8.4. By Application
• 8.5. By End-user
• 8.6. By Region

9. Macro Environment and Industry Structure

• 9.1. Supply Demand Analysis
• 9.2. Import Export Analysis
• 9.3. Supply/Value Chain Analysis
• 9.4. PESTEL Analysis
  • 9.4.1. Political Factors
  • 9.4.2. Economic System
  • 9.4.3. Social Implications
  • 9.4.4. Technological Advancements
  • 9.4.5. Environmental Impacts
  • 9.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 9.5. Porter's Five Forces Analysis
  • 9.5.1. Supplier Power
  • 9.5.2. Buyer Power
  • 9.5.3. Substitution Threat
  • 9.5.4. Threat from New Entrant
  • 9.5.5. Competitive Rivalry

10. Market Dynamics

• 10.1. Growth Drivers
• 10.2. Growth Inhibitors (Challenges, Restraints)

11. Key Players Landscape

• 11.1. Competition Matrix of Top Five Market Leaders
• 11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2022)
• 11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
• 11.4. SWOT Analysis (For Five Market Players)
• 11.5. Patent Analysis (If Applicable)

12. Pricing Analysis

13. Case Studies

14. Key Players Outlook

• 14.1. Thermo Fisher Scientific, Inc.
  • 14.1.1. Company Details
  • 14.1.2. Key Management Personnel
  • 14.1.3. Products & Services
  • 14.1.4. Key Market Focus & Geographical Presence
  • 14.1.5. Financials (As Reported)
  • 14.1.6. Recent Developments
• 14.2. F. Hoffmann-La Roche AG
• 14.3. QIAGEN NV
• 14.4. Guardant Health, Inc.
• 14.5. Veracyte, Inc.
• 14.6. Myriad Genetics, Inc.
• 14.7. Biocept, Inc.
• 14.8. NeoGenomics Laboratories, Inc.
• 14.9. Adaptive Biotechnologies Corporation
• 14.10. DermTech, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

15. Strategic Recommendations

16. About Us & Disclaimer